Body Composition and Very-Low-Density-Lipoprotein-Triglycerides (VLDL-TG) Kinetics
|ClinicalTrials.gov Identifier: NCT00646698|
Recruitment Status : Completed
First Posted : March 28, 2008
Last Update Posted : March 28, 2008
Context: Upper body obese (UBO) subjects are more likely to develop cardiovascular disease (CVD) than lower body obese (LBO) or lean. This may in part be caused by greater hepatic secretion of very-low-density-lipoprotein-triglycerides (VLDL-TG).
Objective: To assess the impact of body composition and insulin sensitivity on basal VLDL-TG turnover in women.
|Condition or disease|
|Obesity Insulin Resistance|
Body composition is an important predictor of obesity related life-style diseases. Thus, preferential accumulation of adipose tissue in the abdominal region has been demonstrated to be associated with greater risk of developing CVD and insulin resistance than accumulation in lower body depots. The reason for this is not yet fully understood, but there are indications that upper body fat depots contain larger and more lipolytically active adipocytes resulting in an excess hepatic delivery of FFAs in upper body obese individuals. As several lines of experimental evidence as well as cross-sectional studies have demonstrated, elevated levels of FFAs affect the cardiovascular system unfavourably and are most likely a major contributor to insulin resistance. A prominent feature of insulin resistance is hypertriglyceridemia, primarily caused by increased levels of very-low-density-lipoprotein (VLDL)-TG.
Even though lipolysis in subcutaneous adipose tissue accounts for the majority (~75 %) of FFAs delivered to the liver, it is conceivable that excess release from visceral adipocytes in UBO individuals impacts VLDL-TG secretion. The reason for this is two-sided: First, upon entry into the liver, FFAs are reesterified to form VLDL-TG which is subsequently secreted. Studies in cell lines as well as whole body investigations in humans have demonstrated, that perturbations of FFA levels may directly affect VLDL-TG output by the liver. Second, elevated levels of FFAs may induce hepatic insulin resistance resulting in increased VLDL-TG output due to a loss of the inhibitory effect of insulin on VLDL-TG secretion. In theory, this combination of excess substrate availability coupled with an unfavorable hormonal milieu (hepatic insulin resistance) could result in increased VLDL-TG production in UBO subjects. A recent study by Mittendorfer et. al. support this notion, since weight loss in UBO women resulted in decreased VLDL-TG production, presumably caused primarily by a decrease in the supply of visceral fatty acids.
Although findings from previous studies have been contradictory as to whether body fat distribution directly affects VLDL-TG clearance, in vitro findings suggest regional differences in lipoprotein lipase (LPL) activity between UBO and LBO women, and VLDL-TG clearance could also be modulated by differences in VLDL associated fatty acid oxidation. To our knowledge, the latter point has not previously been addressed.
The purpose of this study was therefore to investigate differences in VLDL-TG kinetics in women with different body composition phenotypes. Our preliminary hypothesis was that UBO women produce and secrete greater amounts of VLDL-TG than their lower body obese (LBO) or lean counterparts. We also hypothesized, that peripheral clearance would be similar in all groups. Lastly, we wanted to investigate whether the more benevolent lipid profile seen in lean women could in part be a result of a more efficient channeling of VLDL derived fatty acids towards oxidation.
|Study Type :||Observational|
|Actual Enrollment :||30 participants|
|Observational Model:||Case Control|
|Official Title:||Impact of Body Composition on Very-Low-Density-Lipoprotein-Triglycerides Kinetics|
|Study Start Date :||April 2006|
|Actual Primary Completion Date :||February 2007|
|Actual Study Completion Date :||June 2007|
Premenopausal Upper Body Obese (UBO) women with waist-hip ratio > 0.85 and BMI > 28
Premenopausal Lower Body Obese (LBO) women with waist hip ratio < 0.8 and BMI > 28
Premenopausal lean women with BMI < 25
- VLDL-TG kinetics were assessed using a bolus injection of ex-vivo labeled [1-14C]VLDL-TG [ Time Frame: Hours ]
- fractional VLDL-TG derived fatty acid oxidation was measured by 14CO2 trapping from expired air [ Time Frame: Hours ]
- VLDL-TG fat deposition by adipose tissue biopsies [ Time Frame: Hours ]
- Insulin sensitivity by the hyperinsulinemic-euglycemic clamp technique [ Time Frame: 2 hours ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00646698
|Medical Research Laboratories|
|Aarhus, Denmark, 8000|
|Principal Investigator:||Lars C Gormsen, MD PhD||Aarhus University Hospital, Department M|